Model of study | Stress by | MDEs/MDE-miRNAs from | Immune response and morphological changes | Reference |
---|---|---|---|---|
In vitro | ||||
Porcine IPEC-J2 cells | Non-stimulated | Porcine milk | ↑(Cell proliferation, CDX2, IGF-1R, PCNA, miRNAs targeting FAS, SERPINE and p53 pathways); ↓(FAS, SERPINE, p53) | [138] |
Rat IEC-18 cells | Non-stimulated | Rat milk | ↑(Cell viability, proliferation, PCNA, LGR5) | [145] |
Human CCD841 cells or human LS123 cells | Non-stimulated | Human milk | ↑(Cell proliferation, collagen type-I); ↓(twist1, PTEN) in CCD841 cells; = LS123 cells | [146] |
Human LS174T cells | Non-stimulated | Bovine milk | ↑(Mucin secretion, TFF3, MUC2, GRP94) | [147] |
Human FHC cells | Mechanical wound | Human term or preterm milk | ↑(Cell proliferation, migration and wound healing) | [38] |
Porcine IPEC-J2 cells | LPS | Porcine milk | ↑(Cell viability, IκBα); ↓(TLR4, MyD88, p-IκBα, p-NF-κB-p65, p-NF-κB, NF-κB nuclear translocation, Tp53, FAS, Caspase-3, IL-1β, IL-6, TNF-α) | [148] |
Porcine IPEC-J2 cells | LPS | Porcine milk | ↑(Cell viability, IκBα); ↓(TLR4, p-IκBα, p-NF-κB-p65, p-NF-κB, NF-κB, Tp53, p53, FAS, Caspase-3, IL-1β, IL-6, TNF-α) | [149] |
Porcine IPEC-J2 cells | DON | Porcine milk | ↑(Cell viability, proliferation, β-catenin, CCND1, Akt, ZO-1, OCLN, CLDN1, PCNA, miRNAs targeting p53 pathway); ↓(Tp53, FAS, SERPINE1, p21) | [150] |
Rat IEC-6 cells | Hypoxia | Yak milk | ↑(Cell viability, proliferation, PHD-1); ↓(HIF-1α, VEGF, p53) | [151] |
Rat IEC-6 cells | Hypoxia | Yak milk | ↑(Cell viability, Ki67+ cells, PHD-1); ↓(HIF-α, VEGFA, p53, Bax, caspase-3/-9) | [39] |
Rat IEC-6 cells or human FHS-74 cells | Hypoxia/reoxygenation | Human milk | ↑(Living cell count, proliferation); ↓apoptosis | [152] |
Rat IEC-6 cells | H2O2 | Bovine milk | ↑(Cell viability, superperoxide dismutase, glutathione peroxidase); ↓(ROS, LDH, malondialdehyde, NRF2, HO-1) | [153] |
Neonate mice intestinal organoids | LPS | Human colostrum, transitional or matured milk | ↓(Structural damage, TNF-α, TLR4, LGR5, Ki67) | [154] |
Neonate mice intestinal organoids | Hypoxia and LPS | Human raw or pasteurized milk | ↓(Structural damage, IL-6, MPO); ↑(MUC2, goblet cell abundance) | [155] |
In vivo | ||||
Mice | Non-stimulated | Porcine milk | ↑(Small intestinal V/C ratio, CDX2, PCNA, IGF-1R); ↓p53 | [138] |
Mice | Non-stimulated | Bovine milk | ↑(MUC2, RegIIIγ, MyD88, GATA4, IgA, secretory IgA, enterocyte abundance, V/C, cecum surface area) | [156] |
Mice | LPS | Porcine milk | ↓(IL-1β, IL-6, TNF-α); ↑(jejunum morphology, villi structure, V/C ratio) | [148] |
Mice | DON-colitis | Porcine milk | ↓(p53, p21, caspase-3/-9, villi damage); ↑(jejunum villus height, crypt depth, V/C ratio, intestinal length, β-catenin, CCND1, phospho-Akt, ZO-1, OCLN, CLDN1, miRNAs targeting p53 pathway) | [150] |
Mice | DSS-colitis | Human milk | ↑(TGF-β1, miRNAs targeting DNMT1/DNMT3); ↓(colon shortening, inflammatory cell infiltration, tissue damage, lesions, DNMT1/DNMT3, IL-6, TNF-α) | [157] |
Transgenic mice | Tamoxifen-ulcerative colitis | Bovine milk | ↑(Colon length and weight); ↓mucosal injury | [158] |
Neonate rats | Formula feeding and hypoxia-induced NEC | Human preterm milk | ↑(Villus integrity, enterocyte proliferation); ↑(peptides promoting epithelial proliferation, migration, regeneration and immunomodulation) | [38] |
Neonate mice | Formula feeding, LPS and hypoxia-induced NEC | Bovine milk | ↓(Intestinal damage, MPO); ↑(MUC2+/GRP94+ goblet cell abundance) | [147] |
Neonate mice | Formula feeding, LPS and hypoxia-induced NEC | Human milk | ↓(Intestinal damage, severity and incidence of disease) | [152] |
Neonate mice | Formula feeding, LPS and hypoxia-induced NEC | Human raw or pasteurized milk | ↑(Goblet/MUC2+ cell abundance);↓(MPO, IL-6, mucosal injury) | [155] |